Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initial triple oral therapy versus sequential metformin therapy in newly diagnosed type 2 diabetes
ChiCTR2400093342Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of henagliflozin, retagliptin and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Peking University First Hospital. Primary endpoint: HbA1c at 24 weeks. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
henagliflozinretagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400093342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093342.